The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
B7-H1-Induced Apoptosis as a Mechanism of Immune Privilege of Corneal Allografts
Open accessAbstract
The programmed death-1 (PD-1) costimulatory pathway has been demonstrated to play a role in the regulation of immune responses and peripheral tolerance. We investigated the role of this pathway in establishing an immune privilege status of corneal allografts in mice. B7-H1, but not B7-DC or PD-1, was expressed constitutively in the eye, i.e., cornea, iris-ciliary body, and retina. After corneal allografting, PD-1+CD4+ T cells infiltrated and adhered with B7-H1+ corneal endothelium. Blockade of PD-1 or B7-H1, but not B7-DC, led to accelerated corneal allograft rejection. In B7-H1-expressing corneal allografts, apoptosis of the infiltrating PD-1+CD4+ or CD8+ T cells was observed, after which there was allograft acceptance. In contrast, B7-H1 blockade suppressed apoptosis of infiltrating PD-1+ T cells, which led to allograft rejection. In vitro, destruction of corneal endothelial cells by alloreactive T cells was enhanced when the cornea was pretreated with anti-B7-H1 Ab. This is the first demonstration that the constitutive expression of B7-H1 plays a critical role in corneal allograft survival. B7-H1 expressed on corneal endothelial cells maintains long-term acceptance of the corneal allografts by inducing apoptosis of effector T cells within the cornea.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“An active local or peripheral tolerance to prevent runaway immune responses can be induced in some cases through the conversion of T cell to regulatory T cells (Treg) or the apoptosis of infiltrated effector T cells by inhibitory molecules expressed on the retinal pigmented epithelium (RPE) or resident stromal cells [9][10][11].”
From Risk mitigation of immunogenicity: a key to personalized retinal gene therapy (2021) · cites this paper as [11]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025
Ishida, Y., Agata, Y., Shibahara, K., & Honjo, T. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05481.x · Cited by 3,259
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
Latchman, Y., Wood, C. R., Chernova, T., Chaudhary, D., Borde, M., Chernova, I., Iwai, Y., Long, A. J., Brown, J. A., Nunes, R., et al. (2001) · Nature Immunology · doi:10.1038/85330 · Cited by 2,955
Nishimura, H., Nose, M., Hiai, H., Minato, N., & Honjo, T. (1999) · Immunity · doi:10.1016/s1074-7613(00)80089-8 · Cited by 2,749
Dong, H., Zhu, G., Tamada, K., & Chen, L. (1999) · Nature Medicine · doi:10.1038/70932 · Cited by 2,496
Fas Ligand-Induced Apoptosis as a Mechanism of Immune Privilege
Griffith, T. S., Brunner, T., Fletcher, S. M., Green, D. R., & Ferguson, T. A. (1995) · Science · doi:10.1126/science.270.5239.1189 · Cited by 1,990
Autoimmune Dilated Cardiomyopathy in PD-1 Receptor-Deficient Mice
Nishimura, H., Okazaki, T., Tanaka, Y., Nakatani, K., Hara, M., Matsumori, A., Sasayama, S., Mizoguchi, A., Hiai, H., Minato, N., et al. (2001) · Science · doi:10.1126/science.291.5502.319 · Cited by 1,868
Sharpe, A. H., & Freeman, G. J. (2002) · Nature reviews. Immunology · doi:10.1038/nri727 · Cited by 1,759
Medawar, P. B. (1948) · PubMed · Cited by 1,084
Flagged first, then by citations
Research works printed but not linked: 55
- 1993, Ophthalmology, 1728
- 1992, Ophthalmology, 403
- 1990, Surv. Ophthalmol., 325
- 1992, Transplantation, 694
- 1985, Invest. Ophthalmol. Vis. Sci., 23
- 1993, J. Immunol., 1727
- 1987, FASEB J., 199
- 1990, Adv. Immunol., 191
- 1977, J. Immunol., 809
- 2003, Nat. Rev. Immunol., 879
- 2002, J. Leukocyte Biol., 946
- 1989, Reg. Immunol., 42
- 1998, Invest. Ophthalmol. Vis. Sci., 1372
- 1992, Eur. J. Immunol., 165
- 2000, Biochem. Biophys. Res. Commun., 257
- 1998, J. Immunol., 5693
- 1995, J. Clin. Invest., 82
- 2000, Invest. Ophthalmol. Vis. Sci., 4195
- 2000, Br. J. Ophthalmol., 1130
- 1948, Br. J. Exp. Path., 58
- 1977, Adv. Immunol., 1
- 1979, Nature, 326
- 2005, Stem Cells, 507
- 2002, Invest. Ophthalmol. Vis. Sci., 639
- 1984, Invest. Ophthalmol. Vis. Sci., 519
- 1987, Invest. Ophthalmol. Vis. Sci., 1383
- 1986, Transplantation, 248
- 1995, Science, 1189
- 1997, J. Clin. Invest., 396
- 2000, Invest. Ophthalmol. Vis. Sci., 443
- 2000, Invest. Ophthalmol. Vis. Sci., 3032
- 1992, EMBO J., 3887
- 1999, Immunity, 141
- 2002, Nat. Rev. Immunol., 116
- 1999, Nat. Med., 1365
- 2001, J. Exp. Med., 839
- 2000, J. Exp. Med., 1027
- 2001, Nat. Immunol., 261
- 2002, Nat. Med., 793
- 2003, Eur. J. Immunol., 2773
- 2005, J. Immunol., 1586
- 2001, Invest. Ophthalmol. Vis. Sci., 720
- 1997, Eur. J. Immunol., 2490
- 2001, Invest. Ophthalmol. Vis. Sci., 1820
- 2004, Immunity, 327
- 2004, Hepatology, 1312
- 2001, Science, 319
- 2003, J. Exp. Med., 71
- 2003, J. Exp. Med., 63
- 2001, Blood, 1809
- 2003, J. Immunol., 4156
- 2004, J. Clin. Invest., 694
- 2002, Nat. Med., 787
- 1999, Transplantation, 1790
- 1993, Invest. Ophthalmol. Vis. Sci., 3579
Cited by
Sorted by citations
Items 201–208 of 208
Sowbharenya, C. (2021) · Journal of animal research · doi:10.30954/2277-940x.02.2021.2
Liu, R., Yi, R., Chen, X., Yi, G., & Fu, M. (2022) · Transplant Immunology · doi:10.1016/j.trim.2022.101654
Niederkorn, J. Y., & Ligocki, A. J. (2016) · Elsevier eBooks · doi:10.1016/b978-0-128-24465-4.00516-0
Translating IL-2/anti-IL-2 antibody complexes treatment for human tumor immunotherapy
Caudana, P. (2018) · theses.fr (ABES) · doi:10.70675/8a93b17bz416az4e49z9a3bz92c1c8a4cf8c
Immune checkpoint inhibitor (ICI) associated corneal allograft rejection
Marjon, P. P., Echegoyen, J. C., Schanzlin, D. J., Gibbs, P. G., & McClay, E. F. (2026) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2026.101306
Metadata
- Authors
- Hori, J., Wang, M., Miyashita, M., Tanemoto, K., Takahashi, H., Takemori, T., Okumura, K., Yagita, H., & Azuma, M.
- Affiliations
- Nippon Medical School (JP)
- National Institute of Infectious Diseases (JP)
- Juntendo University (JP)
- Department of Immunology, Juntendo University School of Medicine , Tokyo ,
- Tokyo Medical and Dental University (JP)
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2006-11-01
- Volume
- 177
- Issue
- 9
- Pages
- 5928-5935
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W2150372796
- Cited by
- 208
- References
- 58
- Citations by year
- 2026: 1 · 2025: 5 · 2024: 4 · 2023: 3 · 2022: 7 · 2021: 11 · 2020: 16 · 2019: 8 · 2018: 10 · 2017: 8 · 2016: 12 · 2015: 10 · 2014: 7 · 2013: 18 · 2012: 7
- FWCI
- 5.76
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Journal of Immunology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Health Sciences › Medicine › Ophthalmology › Corneal surgery and disorders
- Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
- Keywords
- PD-L1, PD-1, immune privilege, corneal allograft, corneal endothelium, T cell apoptosis, allograft rejection, costimulatory molecules, PD-L2, CD4+ T cells, CD8+ T cells
- MeSH terms
- Animals, Antibodies, Monoclonal, Antigens, Surface, Cornea, Graft Rejection, Graft Survival, Male, Membrane Glycoproteins, Mice, Inbred Strains, Peptides, Transplantation, Homologous, CD4-Positive T-Lymphocytes, Corneal Transplantation, Apoptosis, B7-1 Antigen, CD8-Positive T-Lymphocytes, Endothelial Cells, Apoptosis Regulatory Proteins, Mice, B7-H1 Antigen, Programmed Cell Death 1 Receptor, Programmed Cell Death 1 Ligand 2 Protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
